Literature DB >> 27905076

Improvement of time in therapeutic range with warfarin by pharmaceutical intervention.

Alvaro Víquez-Jaikel1,2, Allan Ramos-Esquivel3.   

Abstract

Background Anticoagulation therapy with warfarin is highly effective for prevention and treatment of thromboembolic disorders. Nevertheless, its management is challenging especially in developing countries, where the medical access is difficult and patient education is poor. Objective To determine the effect of pharmaceutical intervention (PI) on the time in therapeutic range (TTR) of a group of anticoagulated patients from our referral center. Method A group of consecutive outpatients previously treated by usual medical care underwent PI. The intervention consisted in the identification and avoidance of food and drug interactions, the confection of medication schedule charts and education to patients regarding side effects and drug monitoring. Mean TTR before and after PI was compared through the Wilcoxon test for repeated measures. Regression analyses were performed to assess the relationship between a TTR level under 65% and potential explanatory variables. Results Mean TTR before PI was 37.4 ± 23.5% and after PI it raised to 67.0 ± 24.9%. Mean change in TTR was +29.5% (95% CI 14.5-44.6; p < 0.001). Before PI only 4 patients had TTR values above 65%, in contrast to 18 patients after PI. Conclusion Our findings support the efficacy of PI to improve TTR values in patients treated with warfarin.

Entities:  

Keywords:  Anticoagulants; Costa Rica; Drug monitoring; International normalized ratio; Pharmaceutical intervention; Warfarin

Mesh:

Substances:

Year:  2016        PMID: 27905076     DOI: 10.1007/s11096-016-0403-5

Source DB:  PubMed          Journal:  Int J Clin Pharm


  10 in total

Review 1.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Potential benefits of warfarin monitoring by a clinical pharmacist in a long term care facility.

Authors:  Carol Motycka; Carl Kesgen; Steven M Smith; Edgar Alvarez; Kelly Jones
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

3.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

Authors:  Lars Wallentin; Salim Yusuf; Michael D Ezekowitz; Marco Alings; Marcus Flather; Maria Grazia Franzosi; Prem Pais; Antonio Dans; John Eikelboom; Jonas Oldgren; Janice Pogue; Paul A Reilly; Sean Yang; Stuart J Connolly
Journal:  Lancet       Date:  2010-09-18       Impact factor: 79.321

4.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

Review 5.  Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients.

Authors:  Elizabeth S Mearns; Christine G Kohn; Ju-Sung Song; Jessica Hawthorne; Joy Meng; C Michael White; Monika K Raut; Jeff R Schein; Craig I Coleman
Journal:  Thromb Res       Date:  2014-06-02       Impact factor: 3.944

6.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

Review 7.  Determinants and measures of quality in oral anticoagulation therapy.

Authors:  Scott Kaatz
Journal:  J Thromb Thrombolysis       Date:  2007-09-29       Impact factor: 2.300

Review 8.  Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.

Authors:  Yi Wan; Carl Heneghan; Rafael Perera; Nia Roberts; Jennifer Hollowell; Paul Glasziou; Clare Bankhead; Yongyong Xu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2008-11-05

9.  Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic.

Authors:  Stephanie Young; Lisa Bishop; Laurie Twells; Carla Dillon; John Hawboldt; Patrick O'Shea
Journal:  BMC Fam Pract       Date:  2011-08-17       Impact factor: 2.497

10.  Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.

Authors:  Daniel E Singer; Anne S Hellkamp; Jonathan P Piccini; Kenneth W Mahaffey; Yuliya Lokhnygina; Guohua Pan; Jonathan L Halperin; Richard C Becker; Günter Breithardt; Graeme J Hankey; Werner Hacke; Christopher C Nessel; Manesh R Patel; Robert M Califf; Keith A A Fox
Journal:  J Am Heart Assoc       Date:  2013-02-19       Impact factor: 5.501

  10 in total
  5 in total

1.  Pharmacist's interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial.

Authors:  Slaven Falamić; Marko Lucijanić; Maja Ortner Hadžiabdić; Srećko Marušić; Vesna Bačić Vrca
Journal:  Int J Clin Pharm       Date:  2018-07-26

2.  Assessment of oral anticoagulation control at two pharmacist-managed clinics in Brazil.

Authors:  Rogério Guimarães de Lima Silva; Caryne Margotto Bertollo; Isadora Gonçalves Ferreira; Luisa Caldeira Brant; Maria Auxiliadora Parreiras Martins
Journal:  Int J Clin Pharm       Date:  2017-09-20

3.  Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis.

Authors:  Cen Wang; Ye Yu; Wengen Zhu; Jianhua Yu; Gregory Y H Lip; Kui Hong
Journal:  Oncotarget       Date:  2017-08-03

4.  Physician-Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development.

Authors:  Na Wang; Sha Qiu; Ya Yang; Chi Zhang; Zhi-Chun Gu; Yan Qian
Journal:  Front Pharmacol       Date:  2021-06-09       Impact factor: 5.810

5.  Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin.

Authors:  Leiliane Rodrigues Marcatto; Luciana Sacilotto; Letícia Camargo Tavares; Mirella Facin; Natália Olivetti; Celia Maria Cassaro Strunz; Francisco Carlos Costa Darrieux; Maurício Ibrahim Scanavacca; Jose Eduardo Krieger; Alexandre Costa Pereira; Paulo Caleb Junior Lima Santos
Journal:  Front Pharmacol       Date:  2018-09-21       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.